(Q22252980)

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Memantine for patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Treatment of Impaired Cerebral Function in Psychogeriatric Patients with Memantine - Results of a Phase II Double-Blind Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Memantine in the treatment of senile dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Weighing the benefits of new Alzheimer's treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Experimental approaches and drugs in development for the treatment of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Factor structure and scoring of the SKT test battery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment--Geriatric (SCAG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

Mixed dementia: epidemiology, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

A new rating scale for dementia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

inferred from DOI database lookup

7 January 2021

based on heuristic

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

inferred from DOI database lookup

7 January 2021

based on heuristic

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003154.PUB5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD003154.PUB5

1 reference

Consolidated OpenCitations Corpus – April 2017

1606874

1606874

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference